Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis
Excerpt
Tumor Necrosis Factor-α (TNF-α) inhibitors, in particular infliximab, have shown effectiveness as a third-line treatment option in relapsing, refractory sarcoidosis that requires an increased dose of corticosteroids plus one or more anti-sarcoidosis disease modifying drugs [...]
Share and Cite
Afthinos, A.; Pandi, A.; Horti, M.; Papanikolaou, I.C. Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis. Adv. Respir. Med. 2020, 88, 289-291. https://doi.org/10.5603/ARM.2020.0131
Afthinos A, Pandi A, Horti M, Papanikolaou IC. Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis. Advances in Respiratory Medicine. 2020; 88(3):289-291. https://doi.org/10.5603/ARM.2020.0131
Chicago/Turabian StyleAfthinos, Andreas, Aggeliki Pandi, Maria Horti, and Ilias C. Papanikolaou. 2020. "Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis" Advances in Respiratory Medicine 88, no. 3: 289-291. https://doi.org/10.5603/ARM.2020.0131